Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Prostate Cancer Experimental Therapeutics

  • Kedar S. Vaidya
  • Venkata S. Sabbisetti
  • Alexandra Silveira
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6773-2

Synonyms

Definition

Experimental therapy for prostate cancer may be defined as a set of modalities, strategies, drug agents, or various combinations thereof for the treatment of Prostate Cancer. Experimental therapy may include novel indications for approved single-drug agents, combinations of drug agents, and modalities or novel drug agents with intent to demonstrate efficacy equivalent or greater than and improved patient benefit over approved standard of care.

Characteristics

Prostate cancer continues to be one of the most frequently diagnosed cancers among men in the United States and is only second to lung cancerin mortality from disease. Although less understood, a combination of lifestyle and geographic location appears to confer a degree of risk, with the lowest incidence of prostate cancer in China and the highest risk in Scandinavia and North America. Even within North America, the incidence of...

Keywords

Prostate Cancer Androgen Receptor Photodynamic Therapy Advanced Prostate Cancer Prostatic Acid Phosphatase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Barrie SE, Potter GA, Goddard PM et al (1994) Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50:267–273CrossRefPubMedGoogle Scholar
  2. Kelland LR, Abel G, McKeage MJ et al (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53:2581–2586PubMedGoogle Scholar
  3. Krupski TL, Kwan L, Afifi AA et al (2005) Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol 23:7881–7888CrossRefPubMedGoogle Scholar
  4. Lee FY, Borzilleri R, Fairchild CR et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429–1437PubMedGoogle Scholar
  5. Simons JW, Mikhak B, Chang JF et al (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte–macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160–5168PubMedGoogle Scholar

See Also

  1. (2012) Antigen-Presenting Cells. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 209-210. doi:10.1007/978-3-642-16483-5_321Google Scholar
  2. (2012) Atrasentan. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 303. doi:10.1007/978-3-642-16483-5_444Google Scholar
  3. (2012) CD4. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 698. doi:10.1007/978-3-642-16483-5_914Google Scholar
  4. (2012) CD8. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 703. doi:10.1007/978-3-642-16483-5_917Google Scholar
  5. (2012) CYP. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 1036-1037. doi:10.1007/978-3-642-16483-5_1444Google Scholar
  6. (2012) MRI. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2382. doi:10.1007/978-3-642-16483-5_3854Google Scholar
  7. (2012) Microtubule. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2308. doi:10.1007/978-3-642-16483-5_3734Google Scholar
  8. (2012) Prednisone. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2972. doi:10.1007/978-3-642-16483-5_4720Google Scholar
  9. (2012) Promoter. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3004. doi:10.1007/978-3-642-16483-5_4768Google Scholar
  10. (2012) Prostatic Acid Phosphatase. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3072. doi:10.1007/978-3-642-16483-5_6777Google Scholar
  11. (2012) Satraplatin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3335. doi:10.1007/978-3-642-16483-5_6774Google Scholar
  12. (2012) Sipuleucel-T. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3413. doi:10.1007/978-3-642-16483-5_6776Google Scholar
  13. (2012) Taxane. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3614. doi:10.1007/978-3-642-16483-5_5689Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Kedar S. Vaidya
    • 1
  • Venkata S. Sabbisetti
    • 2
  • Alexandra Silveira
    • 3
  1. 1.Global Pharmaceutical Research and DevelopmentAbbott LaboratoriesNorth ChicagoUSA
  2. 2.Renal Division, Department of Medicine, Brigham and Women’s HospitalThe Harvard Clinical and Translational Science CenterBostonUSA
  3. 3.Ocular Molecular Genetics InstituteHarvard Medical School, Massachusetts Eye and Ear InfirmaryBostonUSA